Talk:Axicabtagene ciloleucel

This is the talk page for discussing improvements to the Axicabtagene ciloleucel article.
This is not a forum for general discussion of the article's subject.

Put new text under old text. Click here to start a new topic.
New to Wikipedia? Welcome! Learn to edit; get help.

Article policies

Find medical sources: Source guidelines · PubMed · Cochrane · DOAJ · Gale · OpenMD · ScienceDirect · Springer · Trip · Wiley · TWL

Pharmacology Mid‑importance

	This article is within the scope of WikiProject Pharmacology, a collaborative effort to improve the coverage of Pharmacology on Wikipedia. If you would like to participate, please visit the project page, where you can join the discussion and see a list of open tasks.PharmacologyWikipedia:WikiProject PharmacologyTemplate:WikiProject Pharmacologypharmacology articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Medicine Mid‑importance

	Medicine portal This article is within the scope of WikiProject Medicine, which recommends that medicine-related articles follow the Manual of Style for medicine-related articles and that biomedical information in any article use high-quality medical sources. Please visit the project page for details or ask questions at Wikipedia talk:WikiProject Medicine.MedicineWikipedia:WikiProject MedicineTemplate:WikiProject Medicinemedicine articles
Mid	This article has been rated as Mid-importance on the project's importance scale.

Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Axicabtagene ciloleucel.

PubMed provides review articles from the past five years (limit to free review articles)
The TRIP database provides clinical publications about evidence-based medicine.
Other potential sources include: Centre for Reviews and Dissemination and CDC

Different co-stimulatory domain ?

[1] says "Both of the approved therapies target CD19, a protein expressed in the surface of lymphoma and leukemia cells. The primary difference between the two products is the co-stimulatory domain. Upon binding CD19, the drugs induce different co-stimulatory signals to activate an immune response." - Could explain with RS. - Rod57 (talk) 14:02, 21 October 2017 (UTC)[reply]

What is the risk eg of CRS

Twice the article mentions risk of CRS etc - but what % is the risk, and is it theoretical (based on what) or measured in clinical trials (which) ? - Rod57 (talk) 16:40, 14 December 2017 (UTC)[reply]

There appear to be only 2 other editors besides yourself on this article. You are free to contact them with your inquiry, but will likely be the one to add the % of risk figure to the article.--Quisqualis (talk) 05:49, 15 December 2017 (UTC)[reply]